- Company
- Dinutuximab beta was designated as an orphan drug
- by Eo, Yun-Ho Sep 12, 2023 05:37am
- Dinutuximab beta, an immunotherapy drug administered to neuroblastoma patients, has been designated as an orphan drug. Dinutuximab is a drug from EUSA Pharma, a domestic corporation launched last year, and is currently undergoing formal approval procedures. EUSA Pharma was absorbed and merged into Recordati in 2021. This drug is a chimeric
- Company
- Different progress of three new asthma drugs launched
- by Eo, Yun-Ho Sep 11, 2023 05:29am
- The results of the three types of asthma antibody drugs were different. According to the related industry, at the HIRA Pharmaceutical Reimbursement Evaluation Committee held on the 7th, Nucala of GSK Korea was judged to be appropriate for reimbursement, and Fasenra of AstraZeneca Korea was judged to be non-reimbursable. These drugs are in
- Company
- Rebamipide survives reimb evaluations...a relief
- by Chon, Seung-Hyun Sep 11, 2023 05:29am
- The gastric ulcer treatment ‘rebamipide’ survived Korea’s reimbursement reevaluations. As a result, pharmaceutical companies were able to hold on to their cash cow that brings in KRW 140 billion per year. The Health Insurance Review and Assessment Service concluded that the active substance rebamipide was adequate for reimbursement after d
- Company
- 2nd-gen CML drug approved for reimb following 4th-gen drug
- by Eo, Yun-Ho Sep 11, 2023 05:29am
- Companies are actively working to expand insurance coverage for their prescription chronic myeloid leukemia treatments in Korea. According to the industry sources, Novartis Korea's 4th generation CML treatment ‘Scemblix (asciminib)' was listed for reimbursement last July, and Pfizer Korea's 2nd generation drug 'Bosulif (bosutinib)' also
- Company
- The generic for exclusivity period for Vemlidy ends
- by Kim, Jin-Gu Sep 8, 2023 05:34am
- The generic exclusivity period for the hepatitis B treatment Vemlidy expires on the 15th of this month. Five additional companies that have received approval for generic drugs for this ingredient are expected to enter the market. The pharmaceutical industry is paying attention to whether the original will have an impact on the market share,
- Company
- Appearance of 3rd generation MAO-B inhibitors
- by Eo, Yun-Ho Sep 8, 2023 05:33am
- Parkinson's disease is one of the diseases for which treatment development is slow. It is known that a cure is still impossible, and treatment focuses on suppressing the progression of the disease or alleviating symptoms. Madopar, a representative treatment, is the drug with the greatest anti-Parkinson effect and has become the gold standard
- Company
- Ildong’s new GLP-1 analogue starts clinical trial
- by Chon, Seung-Hyun Sep 7, 2023 05:31am
- Ildong Pharmaceutical announced on the 6th that it recently received investigational new drug (IND) approval from the Ministry of Food and Drug Safety for its ID110521156’s Phase I clinical trial. ID110521156 is Ildong’s new GLP-1 receptor agonist drug candidate. Through the trial, the company plans to evaluate the tolerability, safet
- Company
- Hanmi’s Rolontis post sales of KRW 4.8 bil in H1
- by Chon, Seung-Hyun Sep 5, 2023 05:40am
- Hanmi Pharm’s new drug ‘Rolontis’ has been slowly increasing its influence in the domestic market. In the first half of the year, 2 years into its release, the drug has posted sales of nearly KRW 5 billion. The drug has also been achieving fair results in the early stages of its release in the U.S. According to the pharmaceutical researc
- Company
- HK Inno.N releases its GERD drug K-CAB in Singapore
- by Chon, Seung-Hyun Sep 5, 2023 05:40am
- On the 4th, HK Inno.N announced that it had officially released its novel gastroesophageal reflux disease (GERD) treatment K-CAB in Singapore. HK Inno.N held a symposium to celebrate K-CAB’s launch at the Conrad Centennial Singapore Hotel on August 31st. K-CAB was approved in February in Singapore under the same brand name, K-CAB.
- Company
- Humira market biosimilar share
- by Kim, Jin-Gu Sep 4, 2023 05:04am
- Two years have passed since the biosimilar of the autoimmune disease treatment Humira was launched in the domestic market, and its share in the adalimumab market was found to be around 14%. According to IQVIA, a pharmaceutical market research firm, on the 2nd, the market for 'Adalimumab' ingredients in the first half of this year was 50.1 billio
